drugset / Trial / NCT01488877
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
RandomizedParallel-groupDouble-blindBasic science
Summary
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845 in this population.
Timeline
- Start
- 2012-01
- Primary completion
- 2012-07
- Completion
- 2012-07
Outcome
Outcome not reported
Stopped: “See termination reason in detailed description.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-03882845 | Small molecule | 3 mg | — |
| Subject | PF-03882845 | Small molecule | 10 mg | — |
| Subject | PF-03882845 | Small molecule | 30 mg | — |
| Comparator | Spironolactone | Small molecule | 25 mg | — |